Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced its first named patient sales of its flagship drug Pepaxti in Greece. The sales were made possible through Oncopeptides’ partnership with Ariti S.A., a company specialized on medical and pharmaceutical supply in Greece.
Since receiving the approval of Pepaxti in the European Union and countries in the European Economic Area in August 2022, Oncopeptides have been focusing its launch efforts on Germany while also working to gain market access in other European countries.
“Although still at an early stage, I am happy that we now can supply in Greece and make a difference to patients there with a high unmet need,” says Monica Shaw, CEO of Oncopeptides. “As we work to launch across Europe we need to assess every country individually to find the optimal way to ensure we can start to sell and patients can get access to Pepaxti. We are happy to partner with Ariti S.A. in Greece, as they have a solid experience in multiple myeloma including close relationships with healthcare professionals in the market and good understanding of how to ensure timely access to the drugs within rare disease such as Pepaxti.”
The Vice President and Chief Executive Officer of Ariti S.A., Mr. Kyrkos Serafeim, articulates, “This partnership signifies a momentous stride for our organization as we actively venture into the realm of hematology with a pioneering pharmaceutical compound. We are deeply honored that Greece is one of the first European countries where adult patients with triple-class refractory Multiple Myeloma have already access to this innovative treatment. This partnership represents a significant step forward for Ariti S.A., as it expands into a new disease area, offering novel treatments for patients with hematological malignancies and focusing priority on patient outcomes, through access to innovation”.